In the ongoing multidistrict litigation (MDL) concerning the Paragard intrauterine device (IUD), U.S. District Chief Judge Leigh Martin May of the Northern District of Georgia is reevaluating the bellwether trial schedule following a recent defense verdict. This development comes after a federal jury sided with Teva Pharmaceuticals USA in the first bellwether trial earlier this month.
The litigation centers on allegations that the Paragard IUD is prone to breakage during removal, potentially leading to complications such as surgeries to retrieve broken pieces, infertility, and pain. As of February 2026, approximately 3,867 cases are pending in the MDL, which is being overseen by Judge May in the Northern District of Georgia. ([consumernotice.org](https://www.consumernotice.org/legal/paragard-lawsuits/?utm_source=openai))
Bellwether trials are designed to test representative cases and guide the resolution of similar claims. The first trial concluded with a complete defense verdict for Teva Pharmaceuticals, prompting Judge May to consider adjustments to the bellwether plan. A hearing is scheduled to discuss whether to proceed with the current plan or implement changes in light of the recent verdict.
The outcome of this hearing could influence the trajectory of the remaining cases in the MDL. Legal professionals and stakeholders are closely monitoring the proceedings, as the decisions made may have broader implications for product liability litigation strategies and the management of large-scale MDLs.
Teva Pharmaceuticals, the defendant in this litigation, has experienced a slight increase in its stock price, currently trading at $34.41, up $0.415 (0.01221%) from the previous close. The stock’s intraday high reached $35.48, with a low of $33.79. The latest trade occurred at 21:25 UTC on February 17, 2026.
As the MDL progresses, the legal community awaits further developments that will shape the handling of mass tort cases and the responsibilities of medical device manufacturers.